Nohla Therapeutics is a cellular therapy company driven to provide leading off the shelf therapies for patients with critical diseases. Nohla’s first product is a universal donor cell therapy targeting hematopoietic recovery and chemotherapy induced neutropenia, and is being extended to treat a range of other medical indications. This and other products in the pipeline are based on a unique umbilical cord blood expansion platform developed at the Fred Hutchinson Cancer Research Center
Location: United States, Washington, Seattle
Employees: 51-200
Total raised: $120.5M
Founded date: 2015
Investors 1
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 12.07.2018 | Series B | $11M | - |
| 16.05.2018 | Series B | $45M | 5AM Ventur... |
| 30.11.2016 | Series A | $43.5M | ARCH Ventu... |
| 28.12.2015 | - | $21M | - |
Mentions in press and media 15
| Date | Title | Description |
| 12.07.2018 | Nohla Therapeutics Raises Additional $11M in Second Close of $56M Series B | Nohla Therapeutics, a Seattle, WA-based developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, held the second $11M closing of its Series B financing, bringing the total ... |
| 12.07.2018 | Nohla Therapeutics raises another $11M to support leukemia treatment trials | Nohla Therapeutics founder and Chief Science Officer Colleen Delaney (left) and CEO Kathleen Fanning. (GeekWire Photo / Clare McGrane) Seattle startup Nohla Therapeutics has reeled in another $11 million to further develop its leukemia trea... |
| 16.05.2018 | Nohla Therapeutics Closes $45M Series B Financing | Nohla Therapeutics, a Seattle, WA-based developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases, closed a $45m Series B financing. The round was led by Fidelity Management a... |
| 15.05.2018 | Nohla Therapeutics raises $45M, gets new HQ as it moves novel leukemia treatment closer to market | Nohla Therapeutics Founder and Chief Science Officer Colleen Delaney (left) and CEO Kathleen Fanning. (GeekWire Photo / Clare McGrane) Seattle startup Nohla Therapeutics has raised another huge funding round as it moves its novel leukemia t... |
| 15.05.2018 | Nohla Therapeutics Announces Closing of $45 Million Series B Financing | - |
| 05.04.2017 | GeekWire Awards: Vote for Seattle’s most promising Startup of the Year | Arivale CEO Clayton Lewis and co-founder Lee Hood, center, accept the award for Startup of the Year at the 2016 GeekWire Awards. (GeekWire Photo) The 2017 GeekWire Awards are less than a month away, so that means it’s time to vote for the i... |
| 09.02.2017 | Inside Nohla Therapeutics’ new Seattle biotech lab as Gov. Jay Inslee geeks out on science | Left to right: Governor Jay Inslee, Nohla Chief Medical Officer Colleen Delaney, and Nohla CEO Kathleen Fanning cutting the ribbon to open the new office. (GeekWire Photo / Clare McGrane) It’s no secret that wet lab space is hard to come by... |
| 30.11.2016 | ARCH Venture Leads $43.5M Series A for Nohla Therapeutics | SEATTLE, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Nohla Therapeutics Inc. (Nohla), a biotechnology company pioneering the field of universal donor cellular therapies for treating patients with life threatening hematological disorders and cancers, ... |
| 30.11.2016 | 5AM Ventures Joins $43.5M Series A for Nohla Therapeutics | SEATTLE, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Nohla Therapeutics Inc. (Nohla), a biotechnology company pioneering the field of universal donor cellular therapies for treating patients with life threatening hematological disorders and cancers, ... |
| 30.11.2016 | Nohla Therapeutics Closed $43.5M Series A Financing | Nohla Therapeutics Inc., a Seattle, Washington-based biotechnology company, announced the initial closing of a $43.5M Series A financing round. The round, which brought total financing obtained since inception to $64.6m, was led by new inve... |
Show more